1
|
Kato G, Shimizu Y, Arai Y, Suzuki N, Sugamori Y, Maeda M, Takahashi M, Tamura Y, Wakabayashi N, Murali R, Ono T, Ohya K, Mise-Omata S, Aoki K. The inhibitory effects of a RANKL-binding peptide on articular and periarticular bone loss in a murine model of collagen-induced arthritis: a bone histomorphometric study. Arthritis Res Ther 2015; 17:251. [PMID: 26373710 PMCID: PMC4570694 DOI: 10.1186/s13075-015-0753-8] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2014] [Accepted: 08/10/2015] [Indexed: 12/18/2022] Open
Abstract
INTRODUCTION We designed OP3-4 (YCEIEFCYLIR), a cyclic peptide, to mimic the soluble osteoprotegerin (OPG), and was proven to bind to RANKL (receptor activator of NF-κB ligand), thereby inhibiting osteoclastogenesis. We recently found that another RANKL binding peptide, W9, could accelerate bone formation by affecting RANKL signaling in osteoblasts. We herein demonstrate the effects of OP3-4 on bone formation and bone loss in a murine model of rheumatoid arthritis. METHODS Twenty-four seven-week-old male DBA/1J mice were used to generate a murine model of collagen-induced arthritis (CIA). Then, vehicle or OP3-4 (9 mg/kg/day or 18 mg/kg/day) was subcutaneously infused using infusion pumps for three weeks beginning seven days after the second immunization. The arthritis score was assessed, and the mice were sacrificed on day 49. Thereafter, radiographic, histological and biochemical analyses were performed. RESULTS The OP3-4 treatment did not significantly inhibit the CIA-induced arthritis, but limited bone loss. Micro-CT images and quantitative measurements of the bone mineral density revealed that 18 mg/kg/day OP3-4 prevented the CIA-induced bone loss at both articular and periarticular sites of tibiae. As expected, OP3-4 significantly reduced the CIA-induced serum CTX levels, a marker of bone resorption. Interestingly, the bone histomorphometric analyses using undecalcified sections showed that OP3-4 prevented the CIA-induced reduction of bone formation-related parameters at the periarticular sites. CONCLUSION The peptide that mimicked OPG prevented inflammatory bone loss by inhibiting bone resorption and stimulating bone formation. It could therefore be a useful template for the development of small molecule drugs for inflammatory bone loss.
Collapse
Affiliation(s)
- Genki Kato
- Department of Pharmacology, Division of Bio-Matrix, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Yasuhiro Shimizu
- Department of Orthodontic Science, Division of Oral Health Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Yuki Arai
- Department of Removable Partial Prosthodontics, Division of Oral Health Science, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Natsuki Suzuki
- Department of Removable Partial Prosthodontics, Division of Oral Health Science, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Yasutaka Sugamori
- Department of Pharmacology, Division of Bio-Matrix, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Miki Maeda
- Department of Pharmacology, Division of Bio-Matrix, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan. .,Present address: Department of Trauma-, Hand- and Reconstructive Surgery, Experimental Trauma Surgery, Molecular Skeletal Biology Laboratory, University Medical Center Hamburg-Eppendorf, Heisenberg Group, Martinistrasse 52, 20246, Hamburg, Germany.
| | - Mariko Takahashi
- Department of Pharmacology, Division of Bio-Matrix, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Yukihiko Tamura
- Department of Pharmacology, Division of Bio-Matrix, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Noriyuki Wakabayashi
- Department of Removable Partial Prosthodontics, Division of Oral Health Science, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Ramachandran Murali
- Department of Biomedical Sciences, Research Division of Immunology, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
| | - Takashi Ono
- Department of Orthodontic Science, Division of Oral Health Sciences, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Keiichi Ohya
- Department of Pharmacology, Division of Bio-Matrix, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Setsuko Mise-Omata
- Department of Pharmacology, Division of Bio-Matrix, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| | - Kazuhiro Aoki
- Department of Pharmacology, Division of Bio-Matrix, Graduate School, Tokyo Medical and Dental University, Tokyo, 113-8549, Japan.
| |
Collapse
|
2
|
Murali R, Greene MI. Structure based antibody-like peptidomimetics. Pharmaceuticals (Basel) 2012; 5:209-35. [PMID: 24288089 PMCID: PMC3763629 DOI: 10.3390/ph5020209] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2011] [Revised: 01/17/2012] [Accepted: 01/19/2012] [Indexed: 12/22/2022] Open
Abstract
Biologics such as monoclonal antibodies (mAb) and soluble receptors represent new classes of therapeutic agents for treatment of several diseases. High affinity and high specificity biologics can be utilized for variety of clinical purposes. Monoclonal antibodies have been used as diagnostic agents when coupled with radionuclide, immune modulatory agents or in the treatment of cancers. Among other limitations of using large molecules for therapy the actual cost of biologics has become an issue. There is an effort among chemists and biologists to reduce the size of biologics which includes monoclonal antibodies and receptors without a reduction of biological efficacy. Single chain antibody, camel antibodies, Fv fragments are examples of this type of deconstructive process. Small high-affinity peptides have been identified using phage screening. Our laboratory used a structure-based approach to develop small-size peptidomimetics from the three-dimensional structure of proteins with immunoglobulin folds as exemplified by CD4 and antibodies. Peptides derived either from the receptor or their cognate ligand mimics the functions of the parental macromolecule. These constrained peptides not only provide a platform for developing small molecule drugs, but also provide insight into the atomic features of protein-protein interactions. A general overview of the reduction of monoclonal antibodies to small exocyclic peptide and its prospects as a useful diagnostic and as a drug in the treatment of cancer are discussed.
Collapse
Affiliation(s)
- Ramachandran Murali
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, D5091 Davis Building, 8700 Beverly Blvd., Los Angeles, CA 90048, USA
- Department of Pathology and Laboratory of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| | - Mark I. Greene
- Department of Pathology and Laboratory of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
| |
Collapse
|